AGP Executive Report
Last update: 8 hours agoFDA & Rare Disease: FDA accepted Saol Therapeutics’ SL1009 (DCA) resubmission for pyruvate dehydrogenase complex deficiency, setting a Dec. 30, 2026 PDUFA date. Drug Pipeline Updates: MSD’s tulisokibart (TL1A) hit in hidradenitis suppurativa but failed in systemic sclerosis-associated interstitial lung disease, ending that study. Cancer & Diagnostics: Curium agreed to buy radiopharma rival Lantheus for up to $8B, aiming to expand theranostics and U.S. radiodiagnostics reach. AI in Healthcare: Korea’s health ministry will fund six AI medical-device consortiums to speed clinical validation and real-world adoption. Policy & Access: Wales health board strike action has led to tens of thousands of missed health visitor appointments. Consumer Protection: Michigan’s Supreme Court ruling revives the state’s ability to pursue insulin-pricing claims under the consumer protection act. Clinical Research & Trials: A study warns NICE breast cancer referral criteria may miss up to 95% of younger women at risk. Weight & Brain Biology: Research links weight regain after dieting to brain-driven fat defense mechanisms. Healthcare Workforce: Radiology staffing shortages are expected to keep pushing teleradiology growth.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
